Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Corp.

www.bostonscientific.com

Latest From Boston Scientific Corp.

Medtronic Expects EV ICD To Reduce ICD Complications, Costs

The US pivotal trial of Medtronic’s EV ICD, an implantable cardioverter defibrillator without a transvenous lead, has begun with implants in Illinois and New Zealand. The study will measure device-related complications with the device over six months and test EV ICD's ability to stop ventricular fibrillation.

Clinical Trials Research & Development

TCT 2019: Boston Scientific's Acurate Neo TAVR Misses Endpoint In SCOPE I

Boston Scientific is looking ahead to the next-generation Acurate neo2 valve after results of SCOPE I showed worse rates of kidney injury and severe aortic regurgitation in patients treated with the self-expanding Acurate neo valve than in patients treated with Edwards’ Sapien 3 valve.

Clinical Trials Research & Development

TCT 2019: Evolve Short DAPT And Model U-SUS Study Show Short DAPT Was Comparable To Longer-Term DAPT

Data from two studies that looked at the safety of three-months dual antiplatelet therapy versus longer-term DAPT therapy, presented on 26 September at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, showed non-inferiority for short-term DAPT.

Clinical Trials Research & Development

Feasibility Trial Of Medtronic’s Intrepid Transfemoral TMVR Begins

A new trial will evaluate the feasibility of implanting Medtronic's Intrepid transcatheter mitral valve replacement system through a transfemoral approach after the Intrepid TMVR study showed the feasibility of implanting Intrepid through the transapical approach.

Clinical Trials Innovation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register